J06BB16 • palivizumab • Antiinfectives for systemic use | Immunoglobulins | Specific immunoglobulins
Palivizumab is a monoclonal antibody used for the prevention of severe respiratory syncytial virus (RSV) infections in infants and children at high risk. It works by binding to the F protein of the virus, preventing its replication.
The medication is administered via intramuscular injection, usually once a month during the RSV season, as directed by your doctor. It is important to follow the administration schedule to ensure optimal protection.
Side effects may include injection site reactions, fever, rash, or, in rare cases, severe allergic reactions.
Patients should inform their doctor about any known allergies or other conditions to ensure the safe use of palivizumab.
Substance: palivizumab
Date of last drug list: 01-06-2021
Commercial code: W67585001
Concentration: 100mg / ml
Pharmaceutical form: injectible solution
Quantity: 1
Product type: original
Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).
Manufacturer: ABBVIE S.R.L. - ITALIA
Holder: ASTRAZENECA AB - SUEDIA
Number: 117/1999/04
Shelf life: 3 years
